Biotech Acquisition (BIOT) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BIOT Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Biotech Acquisition's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2022)
(Jun 30 2022) (Mar 31 2022) (Dec 31 2021) (Sep 30 2021)
Assets
Cash & cash equivalent0.01
Cash & Short-term Investments0.00
Prepaid Expense, Current AS0.08
Total Current Assets0.10
Long-term investments231.29
Other Assets, Noncurrent231.29
Total Assets231.39
Liabilities
Accounts Payable and Accrued Liabilities, Current LI3.21
Notes Payable, Related Parties0.30
Other Liabilities, Current0.00
Total Current Liabilities3.52
Total Long-term Debt0.00
Deferred Compensation Liability, Classified, Noncurrent LI8.65
Other liabilities, Noncurrent1.05
Warrant Liabilities Value1.05
Total Liabilities13.22
Stockholders' Equity
Common Stock Value0.00
Retained Earnings / Accumulated Deficit-13.12
Other Equity-231.29
Common Stockholder's Equity-244.41
Non-controlling interests & other231.29
Total Stockholder's Equity-13.12
Liabilities & Stockholder's Equity231.39
4 historic quarters locked

Sign in to unlock the full Biotech Acquisition balance sheet history.

About Biotech Acquisition Co Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-22-074335

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.